Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [06/08/2026 11:07 PDT] Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), Down By 100% ($12.03) From $12.03 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [06/05/2026 08:02 PDT] ENTA Expected to Trade Down After Bearish Patterns Develop
• [06/03/2026 06:55 PDT] ENTA Expected to Trade Down Short Term
• [05/21/2026 06:57 PDT] ENTA Expected to Trade Up After Bullish Patterns Develop
• [05/08/2026 07:09 PDT] ENTA Expected to Trade Down After Bearish Patterns Develop
• [04/14/2026 12:43 PDT] Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), Up By 100% ($13.14) From $13.14 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/10/2026 11:45 PDT] Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), Up By 100% ($12.68) From $12.68 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/10/2026 11:07 PDT] Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), Up By 100% ($12.63) From $12.63 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions